In this company introduction, we speak with David Elsley, President & CEO of Cardiol Therapeutics (NASDAQ/TSX: CRDL), a clinical-stage life sciences company focused on developing therapies to address inflammation-driven cardiovascular diseases.
Cardiol’s lead asset, CardiolRx™, is currently in:
- A Phase 3 trial (Maverick Study) for recurrent pericarditis, enrolling patients at world-leading centers including the Cleveland Clinic, Mayo Clinic, and Mass General.
- A Phase 2 trial (ARCHER Study) for acute myocarditis, where recently released top-line results showed promising impacts on heart size and function.
We also cover:
- The company’s orphan drug designation from the FDA and its implications for market exclusivity.
- Development of CRD-38, a next-generation therapy designed for heart failure – a market with multi-billion-dollar potential.
- Cardiol’s capital position, with funding secured well into 2026.
- Key upcoming milestones for investors, including full data presentations, trial updates, and potential pharma partnerships.
Please email me any further questions you have for David. My email address is Fleck@kereport.com.
Click here to learn more about Cardiol Therapeutics.